Swedish Orphan Biovitrum AB (publ) banner

Intrinsic Value

The intrinsic value of Swedish Orphan Biovitrum AB (publ) (B6E) under the Base Case is 41.84 EUR per share. Compared with the current market price of 41.82 EUR, the stock appears Fairly Valued .

The intrinsic value is the average of valuations using the DCF method and multiples.

Do our valuations actually work? See backtest results .

B6E Intrinsic Value
€41.84
Fairly Valued
Intrinsic Value
Price €41.82
Alert me when B6E is below its intrinsic value
Today €33.47 · 20.0% below the current price

B6E is more expensive than usual. Its valuation was this high or higher on just 12% of days in the past 5 years.

Alternatives to B6E

Fundamental Analysis

What Swedish Orphan Biovitrum AB Does

Biotechnology Health Care

Swedish Orphan Biovitrum, usually called Sobi, is a biopharmaceutical company that develops and sells medicines for rare diseases. Its main focus is on blood disorders, immune-related conditions, and other specialist therapies that treat patients with serious illnesses that are often hard to manage with standard drugs.

Headquarters
Sweden SE
Employees
1 969
IPO date
Sep 15, 2006
Read the full company overview
View Company Overview

Swedish Orphan Biovitrum has a narrow economic moat

No Moat Narrow Wide

Patents and temporary market protections on some of Sobi’s rare-disease medicines delay direct copies, helping it retain sales while rivals develop and test alternatives. Other medicines can still treat the same conditions, so these protections provide a limited barrier rather than keeping all competitors out.

Read the full moat analysis
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · October 27, 2026

Strong portfolio growth led Sobi to raise its full-year revenue outlook, while management kept its adjusted EBITDA margin outlook unchanged.

Open the earnings call
EPS
kr6.89
Expected
kr6.22
Surprise
+10.8%
Stock, day of the call
+1.1%
View Earnings Call

Past 12 months

Continue B6E Research

Decided on Swedish Orphan Biovitrum? Get an email when B6E reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one B6E stock?

The intrinsic value for Swedish Orphan Biovitrum AB (publ) (B6E) under the Base Case is 41.84 EUR.

Is B6E stock undervalued or overvalued?

Compared with the current market price of 41.82 EUR, the stock appears Fairly Valued .

How reliable are our estimates? See how past valuations played out
Back to Top